IFIH1 and dermatomyositis: A case report of four patients on RTX therapy for rapidly progressive lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis showed clinically significant improvement in lung function, though post-treatment infection risk was increased [47].